A study found that PD-L1, PD-L2 and tumor mutation burden from a comprehensive genomic and transcriptomic profiling test independently predicted Keytruda (pembrolizumab) benefit in pan-solid tumors—and when combined in a multivariate signature score—predicted benefit better than PD-L1 or TMB alone.
Table of Contents
YOU MAY BE INTERESTED IN
A confirmation hearing for NCI Director Monica Bertagnolli will take place sometime in October, said Sen. Bernie Sanders (I-VT), chairman of the Senate Health, Education, Labor, and Pensions Committee.
The world’s only biobank that collects healthy breast tissue is once again taking the lead to fulfill another unmet need in breast cancer research: collecting tissue from men to understand how male breast cancer develops.
We see far too many patients with glioblastoma (GBM), an aggressive and almost always fatal malignant brain tumor.
As a founding member of the University of Arizona Cancer Center, David Alberts, MD, and his influence on cancer research epitomizes Isaac Newton’s famous quote, “If I have seen further, it is by standing on the shoulders of giants.”